ELDN Eledon Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ELDN matters now
Eledon Pharmaceuticals, Inc. (ELDN) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.85 with -6.78% on the session and $230.8M in market capitalization; recent performance reads 1-month +9.50% and YTD +159.60%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-39.0M, and EPS of $-0.35. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -29.3%.
The latest indexable market news headline is "Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.00; recent insider activity includes Robinson James A. Jr. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.39
P/S
0.00
EV/EBITDA
-2.94
DCF Value
$0.24
FCF Yield
-29.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-96.8%
ROA
-53.3%
ROIC
-64.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-39.0M | $-0.35 |
| Q4 2025 | $0.00 | $-10.4M | $-0.14 |
| FY 2025 | $0.00 | $-45.6M | $-0.56 |
| Q3 2025 | $0.00 | $-17.5M | $-0.23 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$5.00 - $5.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.97
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.